News
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Formycon to present clinical data on ustekinumab biosimilar FYB202 at EADV Congress in Amsterdam and UEG Week in Vienna. Biosimilar for psoriasis and IBD in final approval phase -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG (ISIN: DE000A1EWVY8) with H1/24 results, maintaining BUY rating and EUR 80 target price. Formycon raises FY/24 guidance due to stronger than expected results -
-
-
-